CHA
RPRX icon

Carmichael Hill & Associates’s Royalty Pharma RPRX Stock Holding History

Carmichael Hill & Associates’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-100
Closed -$5K – 735
2020
Q2 		$5K Buy
+100
New +$4.95K ﹤0.01% 555

Other funds holding RPRX

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RWJF
Robert Wood Johnson Foundation Princeton, New Jersey $81M AUM 0.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Carmichael Hill & Associates's RPRX Position: Q3 2020 in Review

Carmichael Hill & Associates sold out of Royalty Pharma (RPRX) in Q3 2020, closing a stake of 100 shares — an estimated $5K sold.

Carmichael Hill & Associates first reported a position in RPRX in Q2 2020 and held it in 1 quarter. The position peaked at $5K in Q2 2020. 134 funds tracked by Wall St. Rank hold RPRX as of Q3 2020.

  • Carmichael Hill & Associates reported no remaining Royalty Pharma position as of Q3 2020 after selling out during the quarter.
  • Carmichael Hill & Associates sold 100 Royalty Pharma shares in Q3 2020, an estimated $5K.
  • Carmichael Hill & Associates first reported a position in Royalty Pharma in Q2 2020 and held it in 1 quarter.
  • Carmichael Hill & Associates's Royalty Pharma position peaked at $5K in Q2 2020.
  • 134 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2020.

Based on Carmichael Hill & Associates's 13F filing for Q3 2020, filed 12 Nov 2020.